share_log

瑞普生物(300119.SZ)：设有合成生物技术平台，平台拥有基因编辑、基因合成、细胞改造、多组学联用等多项领先技术

Ruipu Biology (300119.SZ): It has a synthetic biotechnology platform with many leading technologies such as gene editing, gene synthesis, cell modification, and multiomics

Gelonghui Finance ·  May 7 03:32

Gelonghui, May 7 | Ruipu Biology (300119.SZ) said on the investor interactive platform that the company has a synthetic biotechnology platform, which has many leading technologies such as gene editing, gene synthesis, cell modification, protein mining and modification, high-throughput screening, high-throughput analysis, and multiomics, which has promoted the upgrading of the company's synthetic biotechnology in veterinary vaccines, antibody drugs, enzyme preparations, probiotics, and related intermediates. The company has established continuous and stable strategic cooperation with research institutes, universities and colleges such as the Tianjin Institute of Industrial Biotechnology of the Chinese Academy of Sciences and Shanghai Jiaotong University to efficiently advance the project research and development process.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment